Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
7
Expiration
Dec 31, 2026
DTE
48d
Moneyness
ITM
Intrinsic
$0.99
IBRX 7 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.20 | +11.11% | 7 | 706 |
| Nov 20, 2026 | 7d | $0.39 | +34.48% | 99 | 4,908 |
| Nov 27, 2026 | 14d | $0.53 | +0.00% | 10 | 10 |
| Dec 4, 2026 | 21d | $0.63 | +23.53% | 10 | 20 |
| Dec 11, 2026 | 28d | — | — | 0 | 10 |
| Dec 18, 2026 | 35d | $0.85 | +6.25% | 30 | 416 |
| Dec 24, 2026 | 41d | — | — | 0 | 4 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Mar 19, 2027 | 126d | $1.20 | +11.11% | 2 | 544 |
| Apr 16, 2027 | 154d | $1.32 | +3.94% | 1 | 55 |
| May 21, 2027 | 189d | $1.25 | -53.87% | 1 | 16 |
| Aug 20, 2027 | 280d | $1.86 | -7.00% | 5 | 20 |
| Nov 19, 2027 | 371d | $2.08 | +4.00% | 10 | 2,001 |
| Mar 17, 2028 | 490d | $2.30 | +12.20% | 2 | 180 |
| Jan 19, 2029 | 798d | $2.80 | +27.27% | 10 | 86 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.